| DB ID | MyCo_3914 |
| Title | Prospective Evaluation of Aspergillus fumigatus-Specific IgG in Patients With Cystic Fibrosis |
| Year | 2021 |
| PMID | 33553006 |
| Fungal Diseases involved | Allergic bronchopulmonary aspergillosis |
| Associated Medical Condition | Cystic fibrosis |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | Ethical aspects were considered and approval for the study was gained by the Ethics Committee of Charité—Universitätsmedizin Berlin, Germany (Number EA2/121/16). |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | Af specific IgG (Gm3) |
| Biomarker Full Name | Aspergillus fumigatus specific Immunoglobulin G (Gm3) |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Germany |
| Cohort | This prospective study was conducted between January 2016 and December 2019 at Christiane Herzog Cystic Fibrosis Center, Charité—Universitätsmedizin Berlin, Germany. Here collected sera from 109 patients with CF, ages 6–69 years, independent of their history of Af related conditions. |
| Cohort No. | 109 |
| Age Group | Jun-69 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | Immunological assay |
| Analysis Method | ImmunoCAP system analysis |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | ImmunoCAP system analysis |
| Up Regulation Down Regulation | Decrease |
| Sequence Data | None |
| External Link | None |
